Is BLCO a Buy? What to Consider in 2026
Last updated July 2026
Short answer
The bull case for Bausch + Lomb (BLCO) rests on Margin and EBITDA expansion: After years of underearning, Bausch + Lomb has been driving structural cost changes and pricing discipline. Revenue (TTM) is ~$5.2B. If you believe that thesis holds, the real questions become position sizing and overlap, not timing. The main risk to that view: The dominant overhang is Bausch Health's roughly $20 billion of consolidated debt and the repeatedly delayed separation, which caps BLCO's valuation and creates forced-seller and solvency-test risk. Whether BLCO is a buy comes down to whether you believe the thesis. This is informational, not a recommendation, and Walnut is not an investment adviser.
Bausch + Lomb is one of the oldest and best-known names in eye health, operating across three segments: Vision Care (roughly 57% of sales, spanning contact lenses like Biotrue and lens-care solutions plus consumer eye drops such as LUMIFY and PreserVision supplements), Pharmaceuticals (around 25%, led by the dry-eye drug MIEBO and international brands), and Surgical (about 18%, including intraocular lenses, phacoemulsification systems and cataract and retina instruments). Full-year 2025 revenue reached roughly $5.1 billion, and the company sells into the structurally growing markets of an aging population, rising myopia and expanding cataract volumes. The investment picture is a mix of genuine operating improvement and unresolved corporate complexity. Q1 2026 revenue grew about 9% year over year to roughly $1.24 billion with adjusted EBITDA nearly doubling, prompting management to raise full-year guidance. At the same time, Bausch + Lomb remains roughly 88% owned by heavily indebted parent Bausch Health, whose long-delayed separation (via spin-off or outright sale) continues to cap the valuation. Layered on top are the residual effects of the 2025 enVista intraocular-lens recall and the company's own leverage, making this a name where the story matters as much as the numbers.
What's the case for buying BLCO?
1. Margin and EBITDA expansion
After years of underearning, Bausch + Lomb has been driving structural cost changes and pricing discipline. Q1 2026 adjusted EBITDA rose roughly 59% year over year, and management raised full-year adjusted EBITDA guidance toward the $1.01 to $1.06 billion range, signaling that the profitability inflection may be durable rather than a one-off.
2. Pharmaceuticals and MIEBO ramp
The pharmaceuticals segment posted the fastest growth in early 2026, led by the dry-eye drug MIEBO and international brands. Dry-eye disease is a large, underserved market, and continued MIEBO uptake gives the company a branded growth engine to offset slower U.S. generics.
3. Secular eye-care demand and surgical recovery
An aging global population, rising rates of myopia and growing cataract-surgery volumes support steady demand across contact lenses and surgical devices. The enVista intraocular-lens franchise returned to full production and reached pre-recall sales levels by late 2025, restoring its role in the premium IOL segment.
4. Separation catalyst from Bausch Health
Bausch Health still owns the large majority of BLCO and has explored both a spin-off and a sale for years. A clean separation, if it clears solvency hurdles, could remove the control discount and let BLCO trade closer to eye-care peers, though timing remains uncertain.
What are the risks to BLCO?
The dominant overhang is Bausch Health's roughly $20 billion of consolidated debt and the repeatedly delayed separation, which caps BLCO's valuation and creates forced-seller and solvency-test risk. Bausch + Lomb carries its own meaningful leverage (several billion dollars of debt), so rising rates or slower EBITDA growth would pressure the balance sheet. The 2025 enVista recall, tied to toxic anterior segment syndrome, is estimated to weigh on 2026 revenue by roughly $78 million and could linger as a brand and litigation risk. The company remains net-loss-making on a GAAP basis, and competition from far larger and better-capitalized rivals like Alcon, Johnson & Johnson and CooperVision is intense across every segment.
How is BLCO valued? (as of July 2026)
Snapshot for BLCO as of July 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.
- Revenue (TTM): ~$5.2B
- FY2026 revenue guidance: ~$5.42B to $5.52B
- Q1 2026 revenue: ~$1.24B (+9% YoY)
- FY2026 adj. EBITDA guidance: ~$1.01B to $1.06B
- Q1 2026 net loss: ~$71M (narrowed from ~$212M)
- Enterprise value: ~$10B
BLCO is not yet consistently GAAP-profitable, so investors lean on adjusted EBITDA and revenue growth rather than earnings multiples. Eye-care peers such as Alcon and The Cooper Companies have traded near 18 to 20 times EV/EBITDA, versus a lower multiple for BLCO that reflects the Bausch Health control discount and leverage. Closing that gap depends heavily on the separation resolving and margins continuing to expand.
How do you decide if BLCO is a buy?
Rather than asking whether BLCO is a buy in the abstract, it tends to help to answer four questions:
- Thesis: do you believe the case above, and is it still true today?
- Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
- Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
- Overlap: check whether you already hold BLCO indirectly through an index or sector ETF before adding more.
For the full picture, see the BLCO stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about BLCO against your real portfolio and see your actual exposure before deciding.
The bottom line on BLCO
The bottom line: Bausch + Lomb's story right now is Margin and EBITDA expansion, with revenue (ttm) at ~$5.2B. If you believe that narrative continues, the call is about sizing BLCO sensibly and checking overlap with what you own; if you doubt it (the risk: the dominant overhang is Bausch Health's roughly $20 billion of consolidated debt and the repeatedly delayed separation, which caps BLCO's valuation and creates forced-seller and solvency-test risk.), it is not for you. Decide from the thesis, not the ticker. Walnut is not an investment adviser.
Build a basket around BLCO with Walnut
Use Bausch + Lomb as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
Is BLCO a good stock to buy right now?
+
The case for Bausch + Lomb right now is Margin and EBITDA expansion, with revenue (ttm) at ~$5.2B. If you believe that thesis holds, BLCO is a way to own it and the real questions are sizing and overlap, not timing; the main risk to that view is the dominant overhang is Bausch Health's roughly $20 billion of consolidated debt and the repeatedly delayed separation, which caps BLCO's valuation and creates forced-seller and solvency-test risk. So it comes down to whether you believe the thesis. Walnut is not an investment adviser and this is not a recommendation.
What does Bausch + Lomb do?
+
Bausch + Lomb is one of the oldest and best-known names in eye health, operating across three segments: Vision Care (roughly 57% of sales, spanning contact lenses like Biotrue and
What are the main risks of BLCO?
+
The dominant overhang is Bausch Health's roughly $20 billion of consolidated debt and the repeatedly delayed separation, which caps BLCO's valuation and creates forced-seller and solvency-test risk. Bausch + Lomb carries its own meaningful leverage (several billion dollars of debt), so rising rates or slower EBITDA growth would pressure the balance sheet. The 2025 enVista recall, tied to toxic anterior segment syndrome, is estimated to weigh on 2026 revenue by roughly $78 million and could linger as a brand and litigation risk. The company remains net-loss-making on a GAAP basis, and competition from far larger and better-capitalized rivals like Alcon, Johnson & Johnson and CooperVision is intense across every segment.
What does Bausch + Lomb (BLCO) do?
+
It is a global eye-health company selling contact lenses, lens-care solutions and consumer eye drops (Vision Care), prescription eye medicines like the dry-eye drug MIEBO (Pharmaceuticals), and cataract, retina and other surgical devices including intraocular lenses (Surgical).
Is BLCO profitable?
+
BLCO is growing revenue and adjusted EBITDA quickly, but it still reports GAAP net losses. Q1 2026 revenue rose about 9% to roughly $1.24 billion while the net loss narrowed to about $71 million from roughly $212 million a year earlier.
Why does BLCO trade at a discount to eye-care peers?
+
Bausch + Lomb is roughly 88% owned by heavily indebted parent Bausch Health, whose long-delayed separation and about $20 billion of consolidated debt create a control overhang and forced-seller risk that peers such as Alcon and CooperVision do not carry.
What is the Bausch Health separation about?
+
Bausch Health has tried since 2020 to fully separate its majority stake in BLCO through a spin-off or sale. Progress has been complicated by the parent's debt load and the need to pass a solvency test, leaving the timing and outcome uncertain.
Walnut is informational and is not an investment adviser. This page is educational and not a recommendation to buy or sell BLCO; figures are approximate and dated, and your own situation, time horizon, and risk tolerance should drive any decision. Verify current data before investing.